AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$RCKT

Wilson Martin sold $256K of RCKT

Wilson Martin (General Counsel) sold 75,364 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.40 ($0.26M total) on 2026-09-11.

Original reporting
SEC EDGAR · Wilson Martin
Published Sep 16, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Bearish
medium confidence
Mentioned
$RCKT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment but is modest in scale.

02

Market read

A small insider sale that may cause slight short‑term price pressure.

03

What to watch

Potential upcoming clinical trial data or partnership announcements that may offset the negative signal.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026-09-11

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$RCKTBearishMedium confidence
Context

General Counsel Wilson Martin sold 75,364 shares of Rocket Pharmaceuticals for $256,463 on 2026-09-11.

Expected impact

Potential modest downward pressure on RCKT price in the short term.

Evidence & confidence

The sale size is small relative to holdings and market cap, so impact is likely limited.

Market effects

Sector

Minimal effect on biotech sector; insider sales are common and rarely move sector sentiment.

Regional

No regional impact beyond the company's own stock.

Global

Limited global relevance; only affects investors tracking RCKT.

Counterpoint

What could challenge this read

The sale could be unrelated to company prospects, e.g., personal liquidity needs.

Key entities

  • Company
    Rocket Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RCKT.

  • Person
    Wilson Martin

    General Counsel of Rocket Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

OCT 8
$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

gurufocus.com5 min
OCT 8
$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

investing.com2 min
OCT 8
$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.

indianpharmapost.com2 min